Daptomycin in vitro susceptibility in European Gram-positive clinical isolates.
about
Daptomycin in paediatrics: current knowledge and the need for future researchDaptomycin for methicillin-resistant Staphylococcus epidermidis native-valve endocarditis: a case report.In vitro activity of daptomycin in combination with β-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci.Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin resistant and methicillin sensitive S.aureus from the Oslo area.Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model.Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.Pharmacokinetics and dialysate levels of daptomycin given intravenously in a peritoneal dialysis patient.Daptomycin in vitro activity tested against Gram-positive strains collected from European and Latin American medical centers in 2003.Infective endocarditis caused by daptomycin-resistant Enterococcus faecalis: a case report.
P2860
Q27006038-4EAE2AF4-2548-4B2B-AA0C-58D6FF778B42Q33718381-ADA84CD2-BB01-4D38-B6AE-F9D6FA6B86E0Q35746209-2D373E0C-D9B6-44FD-996C-177BA4301D30Q35782816-FDC0705C-C747-4809-9ACC-15C655F1997FQ36718474-4AC76560-106B-46BD-9F61-AFA983CCEA29Q40174540-80BDA7DB-5D5E-4430-ADB6-5F48BAC747BFQ42217460-D65EC7BF-A2A2-45C2-B31B-63D7A18D1D42Q44579110-DDA55166-F2B3-446C-A42C-CCD13170AD70Q46196638-9C852B9E-9C6D-4648-BFAA-DB30A2C1376AQ46832044-0F459FF8-49ED-46CC-A680-DC10FFE7C036Q51045580-1590AAAF-5B6B-4E9F-80BD-73EE96FBD362
P2860
Daptomycin in vitro susceptibility in European Gram-positive clinical isolates.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Daptomycin in vitro susceptibility in European Gram-positive clinical isolates.
@en
Daptomycin in vitro susceptibility in European Gram-positive clinical isolates.
@nl
type
label
Daptomycin in vitro susceptibility in European Gram-positive clinical isolates.
@en
Daptomycin in vitro susceptibility in European Gram-positive clinical isolates.
@nl
prefLabel
Daptomycin in vitro susceptibility in European Gram-positive clinical isolates.
@en
Daptomycin in vitro susceptibility in European Gram-positive clinical isolates.
@nl
P2093
P1476
Daptomycin in vitro susceptibility in European Gram-positive clinical isolates.
@en
P2093
Ad C Fluit
Dana Milatovic
Franz-Joseph Schmitz
Jan Verhoef
P356
10.1016/J.IJANTIMICAG.2003.12.014
P577
2004-07-01T00:00:00Z